LENGTH OF AUTHORIZATION: Date of service

ADMINISTRATION: Hospital inpatient setting

REVIEW CRITERIA:

Pediatric and Young Adult Relapsed or Refractory (r/r) B-cell Acute Lymphoblastic Leukemia
- Patient is 25 years of age or younger
- Must have diagnosis of B-cell precursor acute lymphoblastic leukemia
- Patient is refractory or in second or later relapse

Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Patient must be 18 years of age or older
- Patient has relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

DOSING:

Pediatric and Young Adult Relapsed or Refractory (r/r) B-cell Acute Lymphoblastic Leukemia:
50kg and less: A single dose of KYMRIAH™ contains 0.2 to 5.0 x 10^6 CAR-positive viable T cells per kg of body weight.

Above 50kg: A single dose of KYMRIAH™ contains 0.1 to 2.5 x 10^8 CAR-positive viable T cells per kg of body weight.

Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma:
A single dose of KYMRIAH™ 0.6 to 6.0 x 10^8 CAR-positive viable T cells.

* Because of the risk of Cytokine Release Syndrome and neurological toxicities, KYMRIAH™ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYMRIAH REMS. Further information is available at www.kymriah-rems.com or at 1-844-4KYMRIAH.